Mucosa-associated lymphoid tissue lymphoma studied with FDG-PET: A comparison with CT and endoscopic findings

Annals of Nuclear Medicine

Volumn 22, Issue 4, 2008, Pages 261-267

  Enomoto, Keisuke ^a   Hamada, Kenichiro ^a   Inohara, Hidenori ^a   Higuchi, Ichiro ^a   Tomita, Yasuhiko ^b   Kubo, Takeshi ^a   Hatazawa, Jun ^a  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b OSAKA MEDICAL CENTER FOR CANCER AND CARDIOVASCULAR DISEASES   (Japan)

Author keywords

FDG; Findings; Lymphoma; MALT; PET

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

ABDOMINAL RADIOGRAPHY; ADULT; AGED; ARTICLE; CANCER PATIENT; CLINICAL ARTICLE; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; FEMALE; FIBERSCOPE ENDOSCOPY; GASTROINTESTINAL ENDOSCOPY; HEAD AND NECK CARCINOMA; HUMAN; INTERMETHOD COMPARISON; LUNG CARCINOMA; MALE; MUCOSA ASSOCIATED LYMPHOID TISSUE LYMPHOMA; MULTIDETECTOR COMPUTED TOMOGRAPHY; ORBIT CANCER; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RADIODIAGNOSIS; STOMACH LYMPHOMA; THORAX RADIOGRAPHY;

ADULT; AGED; ENDOSCOPY; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; LYMPHOMA, B-CELL, MARGINAL ZONE; MALE; MIDDLE AGED; NEOPLASM STAGING; POSITRON-EMISSION TOMOGRAPHY; PREDICTIVE VALUE OF TESTS; RADIOPHARMACEUTICALS; STOMACH NEOPLASMS; TOMOGRAPHY, X-RAY COMPUTED;

EID: 44949098188     PISSN: 09147187     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12149-007-0125-9     Document Type: Article

References (31)

1. Isaacson P, Wright DH. Malignant lymphoma of mucosa-associated lymphoid tissue: a distinctive type of B-cell lymphoma. Cancer 1983;52:1410-1416.
2. Cavalli F, Isaacson PG, Gascoyne RD, Zucca E. MALT lymphomas. Hematology (Am Soc Hematol Educ Program) 2001;1:241-258.
3. Thieblemont C, Berger F, Dumontet C, Moullet I, Bouafia F, Felman P, et al. Mucosa-associated lymphoid tissue lymphoma is a disseminated disease in one third of 158 patients analyzed. Blood 2000;95:802-806.
4. Stokkel MP, ten Broek FW, van Rijk PP. The role of FDG PET in the clinical management of head and neck cancer. Oral Oncol 1998;34:466-471.
5. Flanagan FL, Dehdashti F, Siegel BA. PET in breast cancer. Semin Nucl Med 1998;28:290-302.
6. Bar-Shalom R, Valdivia AY, Blaufox MD. PET imaging in oncology. Semin Nucl Med 2000;30:150-185.
7. Hustinx R, Benard F, Alavi A. Whole-body FDG-PET imaging in the management of patients with cancer. Semin Nucl Med 2002;32:35-46.
8. Elstrom R, Guan L, Baker G, Nakhoda K, Vergilio JA, Zhuang H, et al. Utility of FDG-PET scanning in lymphoma by WHO classification. Blood 2003;101:3875-3876.
9. Hoh CK, Glaspy J, Rosen P, Dahlbom M, Lee SJ, Kunkel L, et al. Whole-body FDG-PET imaging for staging of Hodgkin's disease and lymphoma. J Nucl Med 1997;38:343-348.
10. Zinzani PL, Magagnoli M, Chierichetti F, Zompatori M, Garraffa G, Bendandi M, et al. The role of positron emission tomography (PET) in the management of lymphoma patients. Ann Oncol 1999;10:1181-1184.
11. Spaepen K, Stroobants S, Dupont P, Van Steenweghen S, Thomas J, Vandenberghe P, et al. Prognostic value of positron emission tomography (PET) with fluorine-18 fluorodeoxy-glucose ([18F]FDG) after first-line chemotherapy in non-Hodgkin's lymphoma: is [18F]FDG-PET a valid alternative to conventional diagnostic methods? J Clin Oncol 2001;19: 414-419.
12. Burton C, Ell P, Linch D. The role of PET imaging in lymphoma. Br J Haematol 2004;126:772-784.
13. Hoffmann M, Kletter K, Becherer A, Jager U, Chott A, Raderer M. 18F-fluorodeoxyglucose positron emission tomography (18F-FDG-PET) for staging and follow-up of marginal zone B-cell lymphoma. Oncology 2003;64:336-340.
14. Beal KP, Yeung HW, Yahalom J. FDG-PET scanning for detection and staging of extranodal marginal zone lymphomas of the MALT type: a report of 42 cases. Ann Oncol 2005; 16:473-480.
15. Alinari L, Castellucci P, Elstrom R, Ambrosini V, Stefoni V, Nanni C, et al. 18F-FDG PET in mucosa-associated lymphoid tissue (MALT) lymphoma. Leuk Lymphoma 2006;47:2096-2101.
16. Taal BG, Burgers JM, van Heerde P, Hart AA, Somers R. The clinical spectrum and treatment of primary non-Hodgkin's lymphoma of the stomach. Ann Oncol 1993;4:839-846.
17. Schechter NR, Portlock CS, Yahalom J. Treatment of mucosa-associated lymphoid tissue lymphoma of the stomach with radiation alone. J Clin Oncol 1998;16:1916-1921.
18. Hickeson M, Yun M, Matthies A, Zhuang H, Adam LE, Lacorte L, et al. Use of a corrected standardized uptake value based on the lesion size on CT permits accurate characterization of lung nodules on FDG-PET. Eur J Nucl Med Mol Imaging 2002;29:1639-1647.
19. Boellaard R, Krak NC, Hoekstra OS, Lammertsma AA. Effects of noise, image resolution, and ROI definition on the accuracy of standard uptake values: a simulation study. J Nucl Med 2004;45:1519-1527.
20. Spaepen K, Stroobants S, Dupont P, Thomas J, Vandenberghe P, Balzarini J, et al. Can positron emission tomography with [(18)F]-fluorodeoxyglucose after first-line treatment distinguish Hodgkin's disease patients who need additional therapy from others in whom additional therapy would mean avoidable toxicity? Br J Haematol 2001;115:272-278.
21. Hoffmann M, Wohrer S, Becherer A, Chott A, Streubel B, Kletter K, et al. 18F-fluoro-deoxy-glucose positron emission tomography in lymphoma of mucosa-associated lymphoid tissue: histology makes the difference. Ann Oncol 2006;17:1761-1765.
22. Koga H, Sasaki M, Kuwabara Y, Hiraka K, Nakagawa M, Abe K, et al. An analysis of the physiological FDG uptake pattern in the stomach. Ann Nucl Med 2003;17:733-738.
23. Neumeister P, Hoefler G, Beham Schmid C, Schmit H, Apfelbeck U, Schaider H, et al. Deletion analysis of the p16 tumor suppressor gene in gastrointestinal mucosa associated lymphoid tissue lymphomas. Gastroenterology 1997;112:1871-1875.
24. Du M, Peng H, Singh N, Isaacson PG, Pan L. The accumulation of p53 abnormalities is associated with progression of mucosa-associated lymphoid tissue lymphoma. Blood 1995;86:4587-4593.
25. Du MQ, Isaccson PG. Gastric MALT lymphoma: from aetiology to treatment. Lancet Oncol 2002;3:97-104.
26. Waki A, Kato H, Yano R, Sadato N, Yokoyama A, Ishii Y, et al. The importance of glucose transport activity as the rate-limiting step of 2-deoxyglucose uptake in tumor cells in vitro. Nucl Med Biol 1998;25:593-597.
27. Torizuka T, Tamaki N, Inokuma T, Magata Y, Sasayama S, Yonekura Y, et al. In vivo assessment of glucose metabolism in hepatocellular carcinoma with FDG-PET. J Nucl Med 1995;36:1811-1817.
28. Koga H, Matsuo Y, Sasaki M, Nakagawa M, Kaneko K, Hayashi K, et al. Differential FDG accumulation associated with GLUT-1 expression in a patient with lymphoma. Ann Nucl Med 2003;17:327-331.
29. Spaepen K, Stroobants S, Dupont P, Vandenberghe P, Thomas J, de Groot T, et al. Early restaging positron emission tomography with (18)F- fluorodeoxyglucose predicts outcome in patients with aggressive non-Hodgkin's lymphoma. Ann Oncol 2002;13:1356-1363.
30. Mikhaeel NG, Timothy AR, O'Doherty MJ, Hain S, Maisey MN. 18-FDG-PET as a prognostic indicator in the treatment of aggressive non-Hodgkin's lymphoma-comparison with CT. Leuk Lymphoma 2000;39:543-553.
31. Mikhaeel NG, Hutchings M, Fields PA, O'Doherty MJ, Timothy AR. FDG-PET after two to three cycles of chemotherapy predicts progression-free and overall survival in high-grade non-Hodgkin lymphoma. Ann Oncol 2005;16:1514-1523.